Literature DB >> 30520873

Radioactive drugs emerge from the shadows to storm the market.

Elie Dolgin.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30520873     DOI： 10.1038/nbt1218-1125

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  First approval in sight for Novartis' CAR-T therapy after panel vote.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2017-08-08       Impact factor: 54.908

2.  Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Authors:  Jonathan Strosberg; Ghassan El-Haddad; Edward Wolin; Andrew Hendifar; James Yao; Beth Chasen; Erik Mittra; Pamela L Kunz; Matthew H Kulke; Heather Jacene; David Bushnell; Thomas M O'Dorisio; Richard P Baum; Harshad R Kulkarni; Martyn Caplin; Rachida Lebtahi; Timothy Hobday; Ebrahim Delpassand; Eric Van Cutsem; Al Benson; Rajaventhan Srirajaskanthan; Marianne Pavel; Jaime Mora; Jordan Berlin; Enrique Grande; Nicholas Reed; Ettore Seregni; Kjell Öberg; Maribel Lopera Sierra; Paola Santoro; Thomas Thevenet; Jack L Erion; Philippe Ruszniewski; Dik Kwekkeboom; Eric Krenning
Journal:  N Engl J Med       Date:  2017-01-12       Impact factor: 91.245
  2 in total
  5 in total

Review 1.  Radiotheranostics: a roadmap for future development.

Authors:  Ken Herrmann; Markus Schwaiger; Jason S Lewis; Stephen B Solomon; Barbara J McNeil; Michael Baumann; Sanjiv S Gambhir; Hedvig Hricak; Ralph Weissleder
Journal:  Lancet Oncol       Date:  2020-03       Impact factor: 41.316

2.  Comparison of various radioactive payloads for a human monoclonal antibody to glycoprotein 41 for elimination of HIV-infected cells.

Authors:  Ravendra Garg; Kienna Mills; Kevin J H Allen; Patrick Causey; Randy W Perron; Denise Gendron; Stephen Sanche; Joan W Berman; Miroslaw K Gorny; Ekaterina Dadachova
Journal:  Nucl Med Biol       Date:  2020-02-19       Impact factor: 2.408

Review 3.  Radiopharmaceutical therapy in cancer: clinical advances and challenges.

Authors:  George Sgouros; Lisa Bodei; Michael R McDevitt; Jessie R Nedrow
Journal:  Nat Rev Drug Discov       Date:  2020-07-29       Impact factor: 84.694

4.  In situ Generated <sup>212</sup>Pb-PSMA Ligand in a <sup>224</sup>Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells.

Authors:  Vilde Y Stenberg; Asta Juzeniene; Øyvind S Bruland; Roy H Larsen
Journal:  Curr Radiopharm       Date:  2020

5.  90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years.

Authors:  Kathrin Rieger; Rosaria De Filippi; Ola Lindén; Andreas Viardot; Georg Hess; Kristina Lerch; Peter Neumeister; Andrea Stroux; Caroline A Peuker; Antonio Pezzutto; Antonello Pinto; Ulrich Keller; Christian W Scholz
Journal:  Ann Hematol       Date:  2022-02-12       Impact factor: 3.673
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.